替吉奥联合伊立替康治疗晚期结肠癌的临床疗效

Clinical efficacy of tegafur,gimeracil and oteracil potassium combined with irinotecan in the treatment of advanced colon cancer

目的观察替吉奥联合伊立替康治疗晚期结肠癌的临床疗效。方法采用回顾性分析,收集2021年5月—2022年4月福建医科大学附属龙岩第一医院接诊的102例晚期结肠癌患者的临床资料,按治疗方案不同分为替吉奥组和卡培他滨组,每组51例。替吉奥组采用替吉奥联合伊立替康治疗,卡培他滨组采用卡培他滨联合伊立替康治疗,21 d为1个治疗周期,2组均治疗2~8个周期。比较2组临床疗效,治疗前后血清基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)水平,不良反应及1年生存率。结果替吉奥组客观缓解率高于卡培他滨组(54.90%vs.33.33%,χ^(2)=4.812,P=0.028);治疗后,2组血清MMP-9及VEGF水平均低于治疗前,且替吉奥组低于卡培他滨组(P<0.01);替吉奥组与卡培他滨组不良反应总发生率无显著差异(25.49%vs.33.33%,χ^(2)=0.756,P=0.385);替吉奥组1年生存率高于卡培他滨组(74.51%vs.54.90%,χ^(2)=4.293,P=0.038)。结论替吉奥联合伊立替康治疗晚期结肠癌患者可提高临床疗效,降低血清MMP-9及VEGF水平,用药安全性高,且可提高患者1年生存率。

Objective To observe the clinical efficacy of tegafur,gimeracil and oteracil potassium combined with irinotecan in the treatment of advanced colon cancer.Methods Retrospective analysis was made on the clinical data of 102 advanced colon cancer patients received in Longyan First Hospital Affiliated to Fujian Medical University from May 2021 to April 2022 were collected,and they were divided into TS-1 group and capecitabine group according to the different treatment plans,51 cases in each group.The TS-1 group was treated with tegafur,gimeracil and oteracil potassium combined with irinotecan,and the capecitabine group was treated with capecitabine combined with irinotecan,21 days as one treatment cycle,and both groups were treated for 2 to 8 cycles.The clinical efficacy,the levels of serum MMP-9,VEGF before and after treatment,adverse effects and 1-year survival rate were compared between the two groups.Results The objective remission rate of the TS-1 group was higher than that of the capecitabine group(54.90%vs.33.33%,χ^(2)=4.812,P=0.028).After treatment,the levels of serum MMP-9 and VEGF of two groups were lower than before treatment,and the TS-1 group was lower than the capecitabine group(P<0.01).There was no significant difference in the total incidence of adverse reactions between the TS-1 group and capecitabine group(25.49%vs.33.33%,χ^(2)=0.756,P=0.385).The 1-year survival rate of the TS-1 group was higher than that of the capecitabine group(74.51%vs.54.90%,χ^(2)=4.293,P=0.038).Conclusion Tegafur,gimeracil and oteracil potassium combined with irinotecan in the treatment of advanced colon cancer patients can improve clinical efficacy,reduce serum MMP-9 and VEGF levels,with a high safety profile,and improve the 1-year survival rate of patients.